Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study - Fizazi, K; Scher, HI; Molina, A (Lancet Oncol, 2012)
et al.